> top > docs > PMC:7121452 > spans > 15524-15991 > annotations

PMC:7121452 / 15524-15991 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
482 147-151 Gene denotes ACE2 Gene:59272
483 281-289 Species denotes patients Tax:9606
485 232-240 Disease denotes Covid-19 MESH:C000657245
486 374-382 Disease denotes Covid-19 MESH:C000657245

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T180 399-400 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T181 463-465 http://purl.obolibrary.org/obo/CLO_0008922 denotes S2
T182 463-465 http://purl.obolibrary.org/obo/CLO_0050052 denotes S2

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T143 133-143 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T144 179-184 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T145 247-257 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T146 463-465 Chemical denotes S2 http://purl.obolibrary.org/obo/CHEBI_29387

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T53 0-467 Sentence denotes On the basis of the available evidence, we think that, despite the theoretical concerns and uncertainty regarding the effect of RAAS inhibitors on ACE2 and the way in which these drugs might affect the propensity for or severity of Covid-19, RAAS inhibitors should be continued in patients in otherwise stable condition who are at risk for, are being evaluated for, or have Covid-19 (see text box), a position now supported by multiple specialty societies (Table S2).